Adjusting the screening frequency for individuals at higher risk of HR−/HER2− tumours (e.g., oral contraceptive users [35], premenopausal women with obesity [36]) or HER2+ (e.g., women with high mammographic density [37] or insulin resistance [38])—while carefully considering the potential for overdiagnosis and the cost-effectiveness concerns—may facilitate early tumour detection [39]. The gene discussed is ERBB2; the disease is neoplasm.